Basilea Pharmaceutica ((CH:BSLN)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Basilea Pharmaceutica is conducting a Phase 3 clinical study titled ‘An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections.’ The study aims to evaluate the efficacy and safety of fosmanogepix in treating adult patients with invasive mold infections, a serious condition caused by various multidrug-resistant molds. This study holds significant potential in addressing unmet medical needs in antifungal treatments.
The intervention being tested is fosmanogepix, administered either as an intravenous infusion or an oral tablet. It is designed to treat invasive mold infections, offering a new therapeutic option for patients who have not responded to standard treatments.
The study follows an interventional design with a randomized allocation and a parallel intervention model. It is open-label, meaning both researchers and participants know which treatment is being administered. The primary purpose is treatment-focused, aiming to compare all-cause mortality rates by Day 42.
The study began on March 27, 2025, with primary completion expected within 8 months. The latest update was submitted on August 28, 2025, indicating ongoing recruitment and progress.
This study update could positively impact Basilea Pharmaceutica’s stock performance by enhancing investor confidence in the company’s innovative pipeline. The successful development of fosmanogepix could position Basilea favorably against competitors in the antifungal market, potentially increasing its market share.
The study is ongoing, with further details available on the ClinicalTrials portal.